Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Viatris Inc's Business Segments
Viatris Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
4
Largest Segment
Developed Markets
Total Revenue
$ 3,517
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Developed Markets57.6%
- Greater China19.3%
- Emerging Markets15.3%
- Japan, Australia and New Zealand7.8%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Developed Markets | $ 2,026 | 57.6% |
| Greater China | $ 680 | 19.3% |
| Emerging Markets | $ 537 | 15.3% |
1 more segments available
Sign in to unlock the full Viatris Inc dataset.
Revenue by Product & Service Category - Q1 FY2026
- Brands30.4%
- Generics27.1%
- Lipitor ®13.1%
- Norvasc ®6%
- Lyrica ®3.4%
- EpiPen® Auto-Injectors2.9%
- Creon ®2.8%
- Viagra ®2.7%
- Zoloft ®2.1%
- Celebrex ®1.9%
- Yupelri ®1.8%
- Effexor ®1.8%
- Xalabrands1.1%
- Dymista ®1.1%
- Xanax ®1%
- Amitiza ®1%
- Product and Service, Other0.1%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Brands | $ 1,069 | 30.4% |
| Generics | $ 952 | 27.1% |
| Lipitor ® | $ 462 | 13.1% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
14 more categories available
Sign in to unlock the full Viatris Inc dataset.
Description of Viatris Inc
Viatris Inc. is a global pharmaceutical company focused on providing affordable access to high-quality medicines for patients worldwide. The company was formed as a result of the merger between Mylan N.V. and Pfizer’s Upjohn business in November 2020. Headquartered in Pittsburgh, Pennsylvania, Viatris has operations in more than 165 countries, and its medicines are used by more than one billion people globally.
The company has a diverse portfolio of products that span across various therapeutic areas such as cardiovascular, central nervous system, dermatology, gastroenterology, HIV/AIDS, and oncology. Some of its well-known brands include Lipitor, Advil, Celebrex, and Viagra.
Viatris employs more than 45,000 people worldwide and has a strong commitment to sustainability and corporate social responsibility. The company strives to reduce its environmental footprint by promoting responsible manufacturing practices, sourcing renewable energy, and reducing water usage.
In terms of financials, Viatris had revenues of $11.9 billion in 2020, and its products are sold in more than 165 countries worldwide. The company's market capitalization as of August 2021 is approximately $15 billion.
Viatris leadership is committed to driving growth and innovation by investing in its portfolio, technology, and partnerships with other companies. The company's leadership team is composed of experienced executives with extensive experience in the pharmaceutical industry, including Heather Bresch, CEO, and Rajiv Malik, President.
Overall, Viatris is a global pharmaceutical company focused on delivering high-quality medicines at affordable prices to patients worldwide. The company's diverse portfolio of products, global reach, commitment to sustainability, and strong leadership all contribute to its success and continued growth.
The company has a diverse portfolio of products that span across various therapeutic areas such as cardiovascular, central nervous system, dermatology, gastroenterology, HIV/AIDS, and oncology. Some of its well-known brands include Lipitor, Advil, Celebrex, and Viagra.
Viatris employs more than 45,000 people worldwide and has a strong commitment to sustainability and corporate social responsibility. The company strives to reduce its environmental footprint by promoting responsible manufacturing practices, sourcing renewable energy, and reducing water usage.
In terms of financials, Viatris had revenues of $11.9 billion in 2020, and its products are sold in more than 165 countries worldwide. The company's market capitalization as of August 2021 is approximately $15 billion.
Viatris leadership is committed to driving growth and innovation by investing in its portfolio, technology, and partnerships with other companies. The company's leadership team is composed of experienced executives with extensive experience in the pharmaceutical industry, including Heather Bresch, CEO, and Rajiv Malik, President.
Overall, Viatris is a global pharmaceutical company focused on delivering high-quality medicines at affordable prices to patients worldwide. The company's diverse portfolio of products, global reach, commitment to sustainability, and strong leadership all contribute to its success and continued growth.
Viatris Inc. is a global healthcare company resulting from the merger of Mylan and Upjohn, a division of Pfizer, which was finalized in November 2020. The company is focused on providing access to medicines that address a wide range of health challenges around the world. Viatris operates through various segments and offers a comprehensive portfolio of products and services designed to meet the diverse needs of patients, healthcare professionals, and healthcare systems.
Segments
1. Branded Medications:
- Viatris offers a range of branded prescription medications. These often include treatments for chronic and acute health conditions, including but not limited to cardiovascular diseases, diabetes, mental health disorders, and infectious diseases. The branded segment focuses on innovating and providing treatments that have been thoroughly researched and developed.
2. Generic Medications:
- As one of the largest producers of generic medications, Viatris plays a critical role in providing affordable alternatives to brand-name drugs. This segment comprises a broad spectrum of therapeutic categories, allowing for access to essential medications in various global markets.
3. Over-the-Counter (OTC) Products:
- Viatris also produces non-prescription products, including those for pain relief, allergies, digestive health, and other common ailments. These products enhance health maintenance and wellness among consumers.
4. Biosimilars:
- This segment focuses on the development and commercialization of biosimilar products, which are biologic medical products highly similar to already approved reference products. Biosimilars represent a vital area of growth as they provide cost-effective treatment options for patients requiring complex therapies, particularly in areas such as oncology and autoimmune diseases.
5. Consumer Health Products:
- Viatris develops and markets a selection of consumer health products aimed at improving everyday health and well-being. These products typically address common conditions and are formulated for easy consumer access.
Products
Viatriss portfolio encompasses a wide variety of therapeutic areas, including but not limited to:
- Cardiovascular Health: Medications that manage hypertension, cholesterol levels, and overall heart health.
- Diabetes Care: Products that assist in managing blood glucose levels, including insulins and oral medications.
- Antibiotics: A range of antibiotics to treat various bacterial infections.
- Mental Health: Treatments for depression, anxiety, and other mental health disorders.
- Pain Management: Both acute and chronic pain management options, including analgesics and anti-inflammatory medications.
- Oncology: Medications designed to treat various types of cancers and supportive therapies for cancer patients.
- Autoimmune Diseases: Treatments targeting conditions such as rheumatoid arthritis and lupus.
Services
In addition to its wide array of products, Viatris also provides various services aimed at improving patient outcomes and access to medications:
1. Patient Support Programs:
- Viatris offers programs that assist patients in managing their health conditions and navigating their treatment options. This includes educational resources, financial assistance programs, and adherence support to ensure patients stay on their prescribed medications.
2. Collaborative Partnerships:
- The company works with healthcare providers, pharmacy benefit managers, and government agencies to improve patient access to medications and address public health needs.
3. Clinical Services:
- Viatris conducts clinical trials and collaborates with healthcare professionals to study the effectiveness of its products and explore new treatment avenues. These services contribute to evidence-based practices in healthcare.
4. Regulatory Affairs:
- The company provides regulatory expertise to ensure its products comply with the health regulations of various countries, facilitating smoother market entry and sustainability.
5. Supply Chain Management:
- Viatris has established a robust supply chain network that ensures the availability and timely distribution of medications globally, contributing to improved healthcare delivery systems.
Through these segments, products, and services, Viatris Inc. commits itself to a vision of expanding access to high-quality medicines, enhancing patient outcomes, and addressing the challenges faced by healthcare systems worldwide.
Segments
1. Branded Medications:
- Viatris offers a range of branded prescription medications. These often include treatments for chronic and acute health conditions, including but not limited to cardiovascular diseases, diabetes, mental health disorders, and infectious diseases. The branded segment focuses on innovating and providing treatments that have been thoroughly researched and developed.
2. Generic Medications:
- As one of the largest producers of generic medications, Viatris plays a critical role in providing affordable alternatives to brand-name drugs. This segment comprises a broad spectrum of therapeutic categories, allowing for access to essential medications in various global markets.
3. Over-the-Counter (OTC) Products:
- Viatris also produces non-prescription products, including those for pain relief, allergies, digestive health, and other common ailments. These products enhance health maintenance and wellness among consumers.
4. Biosimilars:
- This segment focuses on the development and commercialization of biosimilar products, which are biologic medical products highly similar to already approved reference products. Biosimilars represent a vital area of growth as they provide cost-effective treatment options for patients requiring complex therapies, particularly in areas such as oncology and autoimmune diseases.
5. Consumer Health Products:
- Viatris develops and markets a selection of consumer health products aimed at improving everyday health and well-being. These products typically address common conditions and are formulated for easy consumer access.
Products
Viatriss portfolio encompasses a wide variety of therapeutic areas, including but not limited to:
- Cardiovascular Health: Medications that manage hypertension, cholesterol levels, and overall heart health.
- Diabetes Care: Products that assist in managing blood glucose levels, including insulins and oral medications.
- Antibiotics: A range of antibiotics to treat various bacterial infections.
- Mental Health: Treatments for depression, anxiety, and other mental health disorders.
- Pain Management: Both acute and chronic pain management options, including analgesics and anti-inflammatory medications.
- Oncology: Medications designed to treat various types of cancers and supportive therapies for cancer patients.
- Autoimmune Diseases: Treatments targeting conditions such as rheumatoid arthritis and lupus.
Services
In addition to its wide array of products, Viatris also provides various services aimed at improving patient outcomes and access to medications:
1. Patient Support Programs:
- Viatris offers programs that assist patients in managing their health conditions and navigating their treatment options. This includes educational resources, financial assistance programs, and adherence support to ensure patients stay on their prescribed medications.
2. Collaborative Partnerships:
- The company works with healthcare providers, pharmacy benefit managers, and government agencies to improve patient access to medications and address public health needs.
3. Clinical Services:
- Viatris conducts clinical trials and collaborates with healthcare professionals to study the effectiveness of its products and explore new treatment avenues. These services contribute to evidence-based practices in healthcare.
4. Regulatory Affairs:
- The company provides regulatory expertise to ensure its products comply with the health regulations of various countries, facilitating smoother market entry and sustainability.
5. Supply Chain Management:
- Viatris has established a robust supply chain network that ensures the availability and timely distribution of medications globally, contributing to improved healthcare delivery systems.
Through these segments, products, and services, Viatris Inc. commits itself to a vision of expanding access to high-quality medicines, enhancing patient outcomes, and addressing the challenges faced by healthcare systems worldwide.